Neisseria meningitidis Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Neisseria meningitidis Infections – Pipeline Review, H2 2017’, provides an overview of the Neisseria meningitidis Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections

The report reviews pipeline therapeutics for Neisseria meningitidis Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neisseria meningitidis Infections therapeutics and enlists all their major and minor projects

The report assesses Neisseria meningitidis Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neisseria meningitidis Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neisseria meningitidis Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

China National Pharmaceutical Group Corp

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

ImmunoBiology Ltd

JN-International Medical Corp

MGB Biopharma Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Neisseria meningitidis Infections - Overview 6

Neisseria meningitidis Infections - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Neisseria meningitidis Infections - Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Neisseria meningitidis Infections - Companies Involved in Therapeutics Development 22

Beijing Minhai Biotechnology Co Ltd 22

Biological E Ltd 22

China National Pharmaceutical Group Corp 22

Chongqing Zhifei Biological Products Co Ltd 23

GlaxoSmithKline Plc 23

ImmunoBiology Ltd 24

JN-International Medical Corp 24

MGB Biopharma Ltd 25

Pfizer Inc 25

Sanofi Pasteur SA 26

Serum Institute of India Ltd 26

Wellstat Vaccines LLC 26

Neisseria meningitidis Infections - Drug Profiles 28

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile 28

(Haemophilus influenzae [serotype B] + meningococcal) vaccine - Drug Profile 29

(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile 30

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile 31

MenBioVax - Drug Profile 32

meningococcal (tetravalent) vaccine - Drug Profile 33

meningococcal [serotype B] vaccine - Drug Profile 34

meningococcal [serotype B] vaccine - Drug Profile 35

meningococcal [serotype B] vaccine - Drug Profile 36

meningococcal [serotype B] vaccine - Drug Profile 37

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile 38

meningococcal [serotypes A, B, C] vaccine - Drug Profile 40

meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile 41

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 42

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 44

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 45

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 46

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 47

meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 48

meningococcal [serotypes A, C, W135] vaccine - Drug Profile 49

meningococcal [serotypes C, Y] vaccine - Drug Profile 50

meningococcal [strain C2135] vaccine - Drug Profile 51

meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine - Drug Profile 52

meningococcal vaccine - Drug Profile 53

meningococcal vaccine 2 - Drug Profile 54

MGBBP-3 - Drug Profile 55

NCL-195 - Drug Profile 58

Neisseria meningitidis [serotype B] vaccine - Drug Profile 59

Neisseria meningitidis [serotype B] vaccine - Drug Profile 60

PF-06886992 - Drug Profile 61

TP-10 - Drug Profile 62

Neisseria meningitidis Infections - Dormant Projects 63

Neisseria meningitidis Infections - Discontinued Products 65

Neisseria meningitidis Infections - Product Development Milestones 66

Featured News & Press Releases 66

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development for Neisseria meningitidis Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Neisseria meningitidis Infections – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017

Neisseria meningitidis Infections – Pipeline by Biological E Ltd, H2 2017

Neisseria meningitidis Infections – Pipeline by China National Pharmaceutical Group Corp, H2 2017

Neisseria meningitidis Infections – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2017

Neisseria meningitidis Infections – Pipeline by GlaxoSmithKline Plc, H2 2017

Neisseria meningitidis Infections – Pipeline by ImmunoBiology Ltd, H2 2017

Neisseria meningitidis Infections – Pipeline by JN-International Medical Corp, H2 2017

Neisseria meningitidis Infections – Pipeline by MGB Biopharma Ltd, H2 2017

Neisseria meningitidis Infections – Pipeline by Pfizer Inc, H2 2017

Neisseria meningitidis Infections – Pipeline by Sanofi Pasteur SA, H2 2017

Neisseria meningitidis Infections – Pipeline by Serum Institute of India Ltd, H2 2017

Neisseria meningitidis Infections – Pipeline by Wellstat Vaccines LLC, H2 2017

Neisseria meningitidis Infections – Dormant Projects, H2 2017

Neisseria meningitidis Infections – Dormant Projects, H2 2017 (Contd..1), H2 2017

Neisseria meningitidis Infections – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Neisseria meningitidis Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports